Clinically, these insights may provide a rational avenue for the expansion of eprenetapopt utility in MDS to include patient selection based on the presence of ring sideroblasts, rather than reliance on TP53 mutation status. This evidence concerns the gene TP53 and myelodysplastic syndrome.